Response-Adapted Intensification With Cyclophosphamide, Bortezomib, and Dexamethasone Versus No Intensification in Patients With Newly Diagnosed Multiple Myeloma (Myeloma XI): A Multicentre, Open-Label, Randomised, Phase 3 Trial
The Lancet Haematology - United Kingdom
doi 10.1016/s2352-3026(19)30167-x
Full Text
Open PDFAbstract
Available in full text
Categories
Date
December 1, 2019
Authors
Publisher
Elsevier BV